| pubmed-article:10036609 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:10036609 | lifeskim:mentions | umls-concept:C0086418 | lld:lifeskim |
| pubmed-article:10036609 | lifeskim:mentions | umls-concept:C0087111 | lld:lifeskim |
| pubmed-article:10036609 | lifeskim:mentions | umls-concept:C0026336 | lld:lifeskim |
| pubmed-article:10036609 | lifeskim:mentions | umls-concept:C0001962 | lld:lifeskim |
| pubmed-article:10036609 | lifeskim:mentions | umls-concept:C0221099 | lld:lifeskim |
| pubmed-article:10036609 | lifeskim:mentions | umls-concept:C0021469 | lld:lifeskim |
| pubmed-article:10036609 | lifeskim:mentions | umls-concept:C2587213 | lld:lifeskim |
| pubmed-article:10036609 | pubmed:issue | 1 | lld:pubmed |
| pubmed-article:10036609 | pubmed:dateCreated | 1999-5-7 | lld:pubmed |
| pubmed-article:10036609 | pubmed:abstractText | This study developed a model of impaired inhibitory control in humans to test the efficacy of treatments for this deficit. Male social drinkers (N = 35) practiced a "go-stop" task that measured response inhibition. They then were assigned to 1 of 5 groups (n = 7) that performed the task under a different treatment. The model of impaired inhibitory control was provided by administering 0.62 g/kg alcohol to 1 group (A), whose response inhibition was compared with a placebo group (P). The other 3 groups received 0.62 g/kg alcohol plus a treatment designed to ameliorate alcohol impairment of inhibitory control: behavioral reinforcement (B), or 4.4 mg/kg caffeine (C), or a combination of both (B + C). Alcohol impaired inhibitory control, and all 3 treatments (B, C, and B + C) counteracted the impairment. The findings indicate that alcohol impairment of response inhibition may provide a useful human model to test conditions that may ameliorate or exacerbate deficits in behavioral control induced by drugs or other factors. | lld:pubmed |
| pubmed-article:10036609 | pubmed:language | eng | lld:pubmed |
| pubmed-article:10036609 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10036609 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:10036609 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10036609 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10036609 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:10036609 | pubmed:month | Feb | lld:pubmed |
| pubmed-article:10036609 | pubmed:issn | 1064-1297 | lld:pubmed |
| pubmed-article:10036609 | pubmed:author | pubmed-author:Vogel-SprottM... | lld:pubmed |
| pubmed-article:10036609 | pubmed:author | pubmed-author:FillmoreM TMT | lld:pubmed |
| pubmed-article:10036609 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:10036609 | pubmed:volume | 7 | lld:pubmed |
| pubmed-article:10036609 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:10036609 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:10036609 | pubmed:pagination | 49-55 | lld:pubmed |
| pubmed-article:10036609 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:10036609 | pubmed:meshHeading | pubmed-meshheading:10036609... | lld:pubmed |
| pubmed-article:10036609 | pubmed:meshHeading | pubmed-meshheading:10036609... | lld:pubmed |
| pubmed-article:10036609 | pubmed:meshHeading | pubmed-meshheading:10036609... | lld:pubmed |
| pubmed-article:10036609 | pubmed:meshHeading | pubmed-meshheading:10036609... | lld:pubmed |
| pubmed-article:10036609 | pubmed:meshHeading | pubmed-meshheading:10036609... | lld:pubmed |
| pubmed-article:10036609 | pubmed:meshHeading | pubmed-meshheading:10036609... | lld:pubmed |
| pubmed-article:10036609 | pubmed:meshHeading | pubmed-meshheading:10036609... | lld:pubmed |
| pubmed-article:10036609 | pubmed:meshHeading | pubmed-meshheading:10036609... | lld:pubmed |
| pubmed-article:10036609 | pubmed:meshHeading | pubmed-meshheading:10036609... | lld:pubmed |
| pubmed-article:10036609 | pubmed:meshHeading | pubmed-meshheading:10036609... | lld:pubmed |
| pubmed-article:10036609 | pubmed:year | 1999 | lld:pubmed |
| pubmed-article:10036609 | pubmed:articleTitle | An alcohol model of impaired inhibitory control and its treatment in humans. | lld:pubmed |
| pubmed-article:10036609 | pubmed:affiliation | Department of Psychology, University of Waterloo, Ontario, Canada. mfillmor@watarts.uwaterloo.ca | lld:pubmed |
| pubmed-article:10036609 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:10036609 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:10036609 | pubmed:publicationType | Controlled Clinical Trial | lld:pubmed |
| pubmed-article:10036609 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:10036609 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:10036609 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:10036609 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:10036609 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:10036609 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:10036609 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:10036609 | lld:pubmed |
